HANALL BIOPHARMA CO.,LTD
Develops innovative medicines for chronic diseases through antibody and small molecule research.
009420 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 대전광역시 대덕구 상서당1길 43, 대전광역시
- Website:
- http://www.hanallbiopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
HanAll Biopharma Co., Ltd. is a global biopharmaceutical company dedicated to the research and development of innovative, first-in-class medicines for patients with incurable and chronic diseases. The company's core mission is centered on pioneering cutting-edge, disease-modifying therapeutics. Its R&D specializes in antibody research, biotherapeutics, and new small molecule discovery. For over 50 years, HanAll has operated a commercial portfolio of pharmaceutical products targeting a range of therapeutic areas, including endocrine, circulatory, and urologic diseases, while advancing its global pipeline to address significant unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-14 00:00 |
Interim Report
반기보고서 (2025.06)
|
Korean | 1.5 MB | ||
| 2025-07-30 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 29.1 KB | ||
| 2025-07-30 00:00 |
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.7 KB | ||
| 2025-07-30 00:00 |
Transaction in Own Shares
자기주식처분결과보고서
|
Korean | 16.5 KB | ||
| 2025-06-02 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 28.7 KB | ||
| 2025-06-02 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-06-02 00:00 |
Major Shareholding Notification
최대주주등소유주식변동신고서
|
Korean | 27.0 KB | ||
| 2025-06-02 00:00 |
Transaction in Own Shares
자기주식처분결과보고서
|
Korean | 16.4 KB | ||
| 2025-05-30 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 758.3 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.5 MB | ||
| 2025-04-30 00:00 |
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.7 KB | ||
| 2025-04-30 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 29.2 KB | ||
| 2025-04-30 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-30 00:00 |
Major Shareholding Notification
최대주주등소유주식변동신고서
|
Korean | 27.0 KB | ||
| 2025-04-30 00:00 |
Transaction in Own Shares
자기주식처분결과보고서
|
Korean | 16.8 KB |
Automate Your Workflow. Get a real-time feed of all HANALL BIOPHARMA CO.,LTD filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for HANALL BIOPHARMA CO.,LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
